

Press release. The world's first software that offers product and patient specific sizing of neurovascular devices in the treatment of brain aneurysm announced it has received the CE Mark.

Montpellier Fr. 06.12.2017

Sim&Cure, a medical technology company focuses on the development and commercialization of a simulation software, Sim&Size®, for devices treating patients with cerebral aneurysm. The simulation can be done during the intervention or pre-intervention.

The CE Mark approval is a significant accomplishment for Sim&Cure as this application required rigorous regulatory review against clinical and safety standards. The CE approval enables the company to market and sell Sim&Size® in the European Union (EU) member countries. The company plans to make Sim&Size® available to all neurointerventional devices.

Sim&Size® offers at the moment two first CE marked modules dedicated to flowdiverters and intrasaccular devices.

FDsize® simulates the deployment and sizing of flowdiverter;
IDsize® simulates the deployment and sizing of intrasaccular devices.

The software platform will soon integrate a third module STsize, that simulates the deployment and sizing of intracranial laser-cut devices.

In a near future, Sim&Size will allow neurointerventionists to perform a full virtual therapeutic planning with all intracranial devices available on the market.

Sim&Size

TO IMPROVE THERAPEUTIC PLANNING

